



FSP 2024 Summer Pathology Conference ACCREDITATION INFORMATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Florida Medical Association designates this live activity for a maximum of *12.5 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CRITERIA FOR SUCCESS

Statements of credit/participation will be awarded based on the participant's attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme. If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by **July 24, 2024**.

ACTIVITY FORMAT

Live

TARGET AUDIENCE

This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.

STATEMENT OF NEED

The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, all participants should be able to:

- List three major updates in The Paris System second edition for Reporting Urinary Cytology
- Describe how low-grade urothelial neoplasia is classified in the second edition of The Paris System
- Define what is meant by "hypochromatic" high grade urothelial carcinoma
- Review the diagnostic categories proposed by The International System for Reporting Serous Fluid Cytology
- Describe how a pelvic washing specimen involved by a serous borderline tumor would be classified according to The International System
- Recognize the differential diagnosis for pelvic washing specimens containing psammomatous calcification associated only with bland-appearing epithelial cells
- Recognize diagnostic features and differential diagnosis in the evaluation of various urine and serous fluid cytology neoplasms



- Recognize the clinical, endoscopic, and histologic features of Inflammatory Bowel Disease and the clinical, endoscopic and histologic clues that allow recognition of mimics of inflammatory bowel disease
- Recognize diagnostic features and differential diagnosis in the evaluation of various neoplasms including breast and gastrointestinal neoplasms
- Discuss frequent challenges and pitfalls that may derail frozen diagnoses in GI specimens, especially pancreatic tumors
- Recognize precautions and utilize necessary methods when dealing with tumors with presurgical neoadjuvant treatment
- Identify the key histopathological features necessary for accurate identification and classification of Triple Negative Breast Cancer (TNBC)
- Review the diagnostic approach for TNBC, including the utilization of ancillary studies such as immunohistochemical staining and molecular testing, to refine diagnosis and guide tailored treatment strategies
- Describe the currently utilized clinically meaningful biomarkers of Triple Negative Breast Cancer
- Describe the diagnostic criteria used to classify intraductal proliferations of the breast, including the morphological features and immunohistochemical markers utilized in the assessment
- Discuss the differential diagnostic challenges encountered with intraductal proliferations, particularly focusing on interpretations from core needle biopsies
- Review the clinical significance of intraductal proliferations of the breast, including their association with risk factors for invasive carcinoma development, such as patient age, family history, and molecular subtypes
- Recognize diagnostic features and differential diagnosis in the evaluation of various neoplasms including breast and gastrointestinal neoplasms
- Recognize various pathologic and clinical features of liver tumors
- Discuss evidence-based strategies to reduce the risk of medical error and improve patients safety
- Discuss the practical applications of ChatGPT in pathology, including data extraction, report generation, and knowledge synthesis

COMMERCIAL SUPPORT AND EDUCATIONAL GRANTS

All commercial support and educational grants will be communicated to attendees in advance of the meeting.

FACULTY AND PLANNER DISCLOSURES

PLANNER DISCLOSURES:

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients except for Dr. Marilyn Bui who disclosed:

- Grant/Research Support:
 - John Cleveland, PhD- Principal Investigator
 - Marusyk, PhD, Phillip Altrock, PhD, David Basanta, PhD- Co-Principal Investigator
 - Robert Gilles, PhD, Bethany Niell, MD, PhD- Co- Principal Investigator
- Consultant/Advisor/Contractor:
 - 2019-2022 Scientific Advisory Board Member of ContextVision AB
 - 2020-Present Scientific Advisory Board Member of Aiforia Technologies Oy
 - 2020-2022 Scientific Advisory Board member of Visiopharm



- 2020-2022 HER2-Low Pathology Advisory Board Member of AstraZeneca
 - Nov 13, 2020 RNA/GEP Scientific Advisory Board member of Foundation Medicine Institute
 - February-April 2021 Group leader of Advances in the Multidisciplinary Care of Patients with Tenosynovial Giant Cell Tumor on a virtual platform by Spire Learning.
 - July 7, 2021 Lete-cel Regional Steering Committee member of GlaxoSmithKline
 - Nov 7, 2021 Caris Life Sciences Advisory panel meeting
 - March, 26, 2022 Sarcoma therapy BioAlas Advisory panel meeting
- Speaker's Bureau:
 - Feb 2, 2021 Merck
 - May 14-15 Osler Review Anatomic Pathology virtual slide review (bone and cytopathology)

All of the relevant financial relationships listed for this individual have been mitigated (planner and moderator).

FACULTY DISCLOSURES:

John Hart, MD- Has nothing to disclose.

Marisel Kagan, JD, MSN, RN, CPHRM, CPPS, CHC, CHPC, CCEP- Has nothing to disclose.

Kun Jiang, MD, PhD- Has nothing to disclose.

Aysegul Sahin, MD- Has nothing to disclose.

Christopher J. VandenBussche, MD, PhD- *All of the relevant financial relationships listed for this individual have been mitigated.*

- **Employee:** Johns Hopkins University School of Medicine
- **Consultant/Advisor/Contractor:** AlxMed

Eric F. Glassy, MD- *All of the relevant financial relationships listed for this individual have been mitigated.*

- **Consultant/Advisor/Contractor:** Leica BioSystems, Gestalt, Evident

DISCLOSURE OF THE FLORIDA MEDICAL ASSOCIATION

It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA's approval of course content for *AMA PRA Category 1 Credits™*, does not constitute an endorsement of the ideas, positions or statements contained therein. Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.